Intrauterine infection and inflammation are recognized as major contributors to the onset of preterm labor. We describe two cases of severe preterm labor with bulging membrane that were treated by intravenous injection of Sivelestat, a neutrophil elastase inhibitor. Ritodrine hydrochloride and magnesium sulfate were intravenously administered for tocolysis, and ampicillin was provided as an antibiotic. Urinary trypsin inhibitor (UTI) was administered transvaginally. Sivelestat was infused intravenously at 4.8 mg kg À1 day À1 through the maternal vein. No side effects were observed. Levels of interleukin (IL)-6 and IL-8 in amniotic fluid decreased, and gestations were prolonged without complications for >1 week. Two healthy infants were delivered. Our experience suggests that multidrug therapy with Sivelestat offers a new therapeutic strategy for preterm labor, but further investigations of the indications, administration period and dosage are required.
Introduction
Intrauterine infection and inflammation are recognized as major contributors to the onset of preterm labor. 1 Many of the approaches used to prevent preterm birth and associated neonatal morbidity are not based on strong evidence, with the exception of progesterone. 2 Sivelestat is a potent, specific inhibitor of neutrophil elastase that can be administered intravenously to inhibit cytokine production. 3 We describe the first report of clinical administration of Sivelestat to pregnant women.
Case 1
Patient A was a 32-year-old, Japanese primigravida woman who was admitted at 23 0/7 weeks gestation due to preterm labor.
On admission, the uterine os was dilated 3 cm with prolapse of a bulging membrane into the vagina, resulting in an hourglass shape and persistent uterine bleeding. Transvaginal ultrasonography showed a fetal foot within the fetal bag in the vagina. Body temperature was 38.0 1C, white blood cell count was 23 700 cells mm À3 and C-reactive protein (CRP) level was 9.43 mg dl À1 . Fetal heart rate monitoring showed a baseline fetal heart rate of 170 beats min À1 , while uterine activity monitoring revealed regular contractions every 3-5 min. Levels of interleukin (IL)-6 and IL-8 in amniotic fluid from amniocentesis were 80 500 and 24 100 pg ml
À1
, respectively. Glucose concentration in amniotic fluid was 46 mg dl
. Gram staining of amniotic fluid yielded negative results. The diagnostic criteria of clinical chorioamnionitis were satisfied.
The patient was intravenously administered ritodrine hydrochloride and magnesium sulfate for tocolysis, and ampicillin as an antibiotic. Daily vaginal washing was performed using saline containing popidone-iodine. A urinary trypsin inhibitor (UTI) was applied transvaginally. Furthermore, after obtaining informed consent from the patient, Sivelestat was infused intravenously at 4.8 mg kg À1 day À1 . Owing to the presence of intrauterine infection, glucocorticosteroids were not administered to accelerate fetal organ maturation, and decrease the risk of respiratory distress syndrome and intraventricular hemorrhage.
Body temperature normalized immediately after treatment, and white blood cell count and CRP level decreased to 7100 cells mm À3 and 0.76 mg dl À1 , respectively. No further evidence of infection was apparent until delivery. Gestation was prolonged without complication for >1 week.
Cesarean delivery was performed at 24 0/7 weeks gestation, owing to onset of labor and foot presentation. A male infant was delivered, weighing 696 g and showing Apgar scores of 2 at 1 min and 5 at 5 min. In umbilical blood, white blood cell count was 4100 cells mm À3 , CRP level was 0.01 mg dl À1 and immunoglobulin M was negative. Levels of IL-6 and IL-8 were 38 500 and 4950 pg ml À1 in amniotic fluid, and 19.4 and 52.3 pg ml À1 in umbilical blood, respectively. Glucose concentration in amniotic fluid was 47 mg dl À1 . Placental histopathology showed only mild chorioamnionitis, but no funisitis.
The neonate was admitted to the neonatal intensive care unit. Mild intraventricular hemorrhage was identified, but no infections or other complications were present. The child has shown normal development for the past 30 months and the mother has experienced no side effects.
Case 2
Patient B was a 22-year-old, Japanese primigravida woman who was admitted at 23 2/7 weeks gestation, owing to preterm labor.
On admission, the uterine os was dilated 3 cm with prolapse of a bulging membrane into the vagina (hourglass shape). Body temperature was 37.6 1C, white blood cell count was 10 600 cells mm À3 and CRP was negative. Basal fetal heart rate was 175 beats min À1 and uterine contractions were irregular. IL-6 and IL-8 levels in amniotic fluid from amniocentesis were 1660 and 3540 pg ml À1 , respectively. Glucose concentration in amniotic fluid was below the level of detection (<10 mg dl À1 ). Gram stain examination of amniotic fluid yielded negative results. The diagnostic criteria for clinical chorioamnionitis were not satisfied.
As with patient A, patient B was administered ritodrine, magnesium sulfate and antibiotics. UTI was applied transvaginally. Sivelestat was administered intravenously at 4.8 mg kg À1 day À1 . As intrauterine infection was suspected, therapy with glucocorticosteroids was avoided. A male infant weighing 693 g was delivered at 25 1/7 weeks gestation. In umbilical blood, CRP was 0.72 mg dl À1 and IgM was negative. IL-6 and IL-8 levels were 879 and 2170 pg ml À1 in amniotic fluid, and 149 and 63.4 pg ml À1 in umbilical blood, respectively. Glucose concentration in amniotic fluid was 93 mg dl À1 . Placental histopathology showed only mild chorioamnionitis, with no funisitis.
The neonate was admitted to the neonatal intensive care unit. No infections or other complications were encountered. The neonate has shown normal development over the past 18 months, and the mother has experienced no side effects.
Discussion
To the best of our knowledge, this represents the first report of clinical administration of Sivelestat to pregnant women. Approximately 40% of preterm births follow preterm labor. 4 Despite renewed efforts to reduce preterm births, the rate has actually increased over the last decade. Severe preterm labor at less than 24 weeks gestation presents a difficult dilemma to both doctors and patients. Conservative management could be selected, but fetal prognosis remains poor in such cases. 5 Epidemiological, microbiological and clinical evidence suggests an association between infection and preterm birth. 4 Strategies for cases of preterm labor in which the presence of subclinical (silent) intrauterine infection, rather than overt intrauterine infection, is suspected may need to use not only tocolytic agents but also anti-inflammatory agents.
Antibiotics are often chosen for inflammation or infection, but using antibiotic therapy prophylactically or therapeutically for preterm labor with intact membranes has failed to show benefits in terms of maternal and neonatal outcomes. 6 A novel meta-analysis by Hutzal et al.
7 measured the effects of antibiotics used for preterm premature rupture of the membranes and spontaneous preterm labor before 34 weeks gestation. The results confirmed that prophylactic antibiotics in preterm premature rupture of the membranes confer benefits with respect to latency and fetomaternal infectious morbidity. In contrast, at the same gestational age, antibiotics used in women in spontaneous preterm labor with intact membrane conferred no benefit with respect to latency. Antibiotics may be effective against bacteria causing inflammation, but may not be effective for any cytokines produced during intrauterine infection.
As evidence, Matsuda et al. 8 reported that the difference in concentrations of IL-6 and IL-8 in umbilical cord blood and cervicovaginal fluid did not vary significantly between women with or without antibiotic therapy during preterm labor. Moreover, Kanayama et al. 9 reported that antibiotics and UTI has a role in the inhibition of preterm delivery through suppression of cytokines and inflammatory mediators.
Some studies have suggested that UTI may be useful for treating preterm labor. 9, 10 On the other hand, Matsuda and Yunohara 10 reported that improvements were not seen in the clinical course of mothers or in neonatal prognosis following severe preterm labor with a bulging membrane prolapsing into the vagina. One explanation may be that intravaginal treatment with UTI is inadequate to maintain the fetal membranes and uterine cervix in severe preterm labor, as in the present cases. Therefore, in terms of not only improved cytokine levels in amniotic fluid but also the duration of gestational prolongation, we felt that Sivelestat administration was effective. The concentration of neutrophil elastase in amniotic fluid was elevated in patients with preterm labor. 11 Peptidase inhibitor 3 inhibits neutrophil elastase and proteinase 3. Gene expression of peptidase inhibitor 3 has been shown to be altered in the membranes of patients with preterm labor. 12 The promoter sequences for peptidase inhibitor 3 show a high degree of variability, and the consequences of variations in peptidase inhibitor 3 mRNA expression levels in chorioamniotic membranes have been characterized. 13 Use of neutrophil elastase inhibitors in patients with severe preterm labor thus seems feasible and physiologically reasonable.
We selected Sivelestat as the only drug currently available in Japanese clinical practice for the treatment of acute lung injury associated with systemic inflammatory response syndrome. The dosage of Sivelestat was fixed at an infusion rate of 4.8 mg kg À1 day À1 , the current standard daily clinical dose for adults.
14 The molecular weight of Sivelestat sodium is estimated as 528. 3 Although no reports have dealt with transplacental effects, Sivelestat may cross the placenta.
When treating a patient in severe preterm labor, we have usually performed multidrug treatment with administration of ritodrine, magnesium sulfate and antibiotics, along with vaginal washing using saline containing popidone-iodine and UTI. We have encountered many patients in clinical practice for whom cytokine levels did not improve and delivery could not be delayed using such treatment without Sivelestat. Sivelestat therapy appears to have improved inflammation and cytokine levels without either maternal or fetal side effects in the present cases. Moreover, in animal models, our previous studies 15 have suggested that Sivelestat with antibiotics has tocolytic effects on preterm labor resulting from intrauterine infection by restraining prostaglandin synthesis that is dependent on cytokine stimulation of the decidua and fetal membranes. Sivelestat inhibits the enzymatic action of neutrophil elastase, but neither inhibits the release of elastase from neutrophils nor prevents accumulation of neutrophils in damaged tissues. 3 Thus, to be effective Sivelestat needs to be administered together with antibiotics. 15 In conclusion, our experience suggests that Sivelestat administration may offer a new therapeutic strategy for treating preterm labor, although further investigations of optimal dosage, timing and duration of administration, transplacental effects, and adverse effects on both mothers and fetuses are required.
